In wake of IP claims tar­get­ing its megablock­buster, BioN­Tech mulls a few next steps of its own

BioN­Tech may have more on its mind than just de­fend­ing it­self against Cure­Vac’s claims that their megablock­buster mR­NA Covid-19 vac­cine Comir­naty vi­o­lat­ed their in-house IP on mes­sen­ger RNA tech.

The big Ger­man biotech con­firmed a re­port in Die Welt that it is “look­ing at all le­gal op­tions” in mount­ing a re­ply, which is be­ing in­ter­pret­ed in press re­ports as a threat it may take its own le­gal steps in the mat­ter. Ex­act­ly what those steps may be, in­clud­ing the pos­si­bil­i­ty of a counter law­suit, BioN­Tech isn’t say­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER